MX2021005453A - Tratamiento de combinacion para hipertension resistente. - Google Patents

Tratamiento de combinacion para hipertension resistente.

Info

Publication number
MX2021005453A
MX2021005453A MX2021005453A MX2021005453A MX2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A
Authority
MX
Mexico
Prior art keywords
combination treatment
resistant hypertension
hypertension
combination
resistant
Prior art date
Application number
MX2021005453A
Other languages
English (en)
Inventor
Jr John C Burnett
Nina Dzhoyashvili
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021005453A publication Critical patent/MX2021005453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen materiales y métodos para tratar la hipertensión (incluida la hipertensión resistente) con una combinación de un péptido natriurético auricular M (MANP) y un agente diurético (por ejemplo, furosemida).
MX2021005453A 2018-11-09 2019-11-08 Tratamiento de combinacion para hipertension resistente. MX2021005453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758009P 2018-11-09 2018-11-09
PCT/US2019/060401 WO2020097421A1 (en) 2018-11-09 2019-11-08 Combination treatment for resistant hypertension

Publications (1)

Publication Number Publication Date
MX2021005453A true MX2021005453A (es) 2021-09-08

Family

ID=70612496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005453A MX2021005453A (es) 2018-11-09 2019-11-08 Tratamiento de combinacion para hipertension resistente.

Country Status (11)

Country Link
US (1) US20220118054A1 (es)
EP (1) EP3877402A4 (es)
JP (1) JP2022506716A (es)
KR (1) KR20210090229A (es)
CN (1) CN113727997A (es)
AU (1) AU2019375988A1 (es)
BR (1) BR112021008841A2 (es)
CA (1) CA3119055A1 (es)
IL (2) IL315007A (es)
MX (1) MX2021005453A (es)
WO (1) WO2020097421A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039392A1 (en) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for determining pgc target dosage
WO2023039453A2 (en) * 2021-09-09 2023-03-16 Mayo Foundation For Medical Education And Research Dual-function polypeptides and methods for use thereof
US20240116990A1 (en) * 2022-09-19 2024-04-11 Mayo Foundation For Medical Education And Research Compositions and Methods of Treatment Using CRRL 191
WO2024178072A1 (en) * 2023-02-22 2024-08-29 Mayo Foundation For Medical Education And Research Methods of treating hypertension with metabolic syndrome using manp

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015135024A1 (en) * 2014-03-14 2015-09-17 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (soc) diuretic treatment
WO2018089601A1 (en) * 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues

Also Published As

Publication number Publication date
JP2022506716A (ja) 2022-01-17
BR112021008841A2 (pt) 2021-08-31
EP3877402A4 (en) 2022-07-27
CN113727997A (zh) 2021-11-30
WO2020097421A1 (en) 2020-05-14
CA3119055A1 (en) 2020-05-14
US20220118054A1 (en) 2022-04-21
KR20210090229A (ko) 2021-07-19
IL315007A (en) 2024-10-01
IL282958A (en) 2021-06-30
EP3877402A1 (en) 2021-09-15
AU2019375988A1 (en) 2021-05-27
IL282958B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
MX2021005453A (es) Tratamiento de combinacion para hipertension resistente.
WO2018132635A8 (en) Methods for analyzing t cell receptors and b cell receptors
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
CL2022003378A1 (es) Péptidos y combinaciones para uso en inmunoterapia contra el cáncer de páncreas y otros cánceres (solicitud divisional 201703235)
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
MX2020003480A (es) Medios y metodos para secuenciacion de peptido de molecula individual.
PE20230381A1 (es) Proteina de union a rgma
MX2020013722A (es) Anticuerpos que comprenden polipeptido insertado en la region de marco 3.
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
EA202191379A1 (ru) Комбинированное лечение nafld и nash
UY37576A (es) Anticuerpos dirigidos a hueso
MX2019014174A (es) Anticuerpo anti-receptor de igf-i.
MX2021005046A (es) Un algoritmo cuantitativo para la endometriosis.
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
MX2019012352A (es) Composiciones, sistemas, kits y metodos para ablacion neural.
WO2020068196A3 (en) Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease
WO2019222400A3 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
MX2020003644A (es) Metodo de martillado de union soldada con filete a solape y estructuras soldadas.
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
ZA202007896B (en) Wear part, bucket, system and method
WO2019094669A3 (en) Self-assembling protein structures and components thereof
EP4246324A3 (en) Apparatus and method for reducing an energy consumption of hardware based on an application state